A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.
Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.
Gilead Sciences inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases
BeiGene Ltd. will partner with Swiss firm Novartis AG to develop, manufacture and commercialize the China-based biotechnology company’s cancer drug tislelizumab.
Life sciences mergers and acquisitions (M&A) activity totaled $159 billion in 2020, down from $306 billion in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY M&A Firepower report
Humanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.
A little more than one year after Gilead Sciences Inc. and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies pulled the plug on that goal as well as others following a Complete Response Letter issued in August 2020.